As more research continues on the role of galectin-3 in a wide range of diseases, the usefulness of Modified Citrus Pectin will continue to grow as well, offering new hope to patients.
I recently shared the latest news in the prevention and treatment of cancer at the American Academy of Anti-Aging Medicine (A4M) Integrative Oncology Fellowship. The June 2011 event held in Las Vegas, Nevada brought together some of the world’s leading medical experts to educate physicians, health practitioners and scientists on advancements in the fields of integrative medicine and cancer care.
During the fellowship, I gave recommendations on holistic and integrative approaches to treating cancer and was thrilled to meet a group of enthusiastic physicians and health providers who are interested in and committed to learning and practicing integrative oncology. It is my belief and experience that integrating the best medical practices — from both East and West — with an open heart guided by love, compassion, and empowerment of the patient can offer true transformation in healthcare.
A large focus of my practice incorporates the most important scientific breakthroughs in integrative and complementary medicine. There is now a significant body of research validating many ancient as well as modern approaches to treating illness using botanical-based medicine. As an Integrative Cancer Physician, a central focus of my practice is to bring together top well-researched treatments from both conventional and natural medicine in order to design each patient’s protocol with an emphasis on the person as a whole.
Groundbreaking New Research on the Role of Galectin-3 Molecules
Inspired by cutting-edge research on natural health solutions, I presented new evidence on the positive effects of Modified Citrus Pectin (derived from the pith of citrus fruit peels) in blocking unhealthy levels of galectin-3 molecules in the body. Galectin-3 is produced naturally by our bodies, but new research proves that elevated levels in the body can lead to serious health conditions like heart disease, fibrosis and metastatic cancer. Modified Citrus Pectin is the only natural galectin-3 blocker. By binding to and blocking excess galectin-3 molecules, Modified Citrus Pectin prevents galectin-3 from wreaking havoc on our bodies. These new discoveries give Modified Citrus Pectin even greater potential in the prevention and treatment of many serious health conditions for which there are currently limited or no treatments available.
Testing For Elevated Galactin-3 Levels
Early detection of any disease is critical for prevention and recovery. A new blood test that measures circulating levels of galectin-3 has been approved by the FDA and most types of health insurance as a useful tool in helping to determine cardiovascular disease risk and prognosis. This test can also be used to determine risks of cancer metastasis. The development and use of this simple blood test by conventional medicine means that galectin-3 is now on its way to being widely accepted and used as a therapeutic target in conditions from congestive heart failure to metastatic cancer, among others.
As more research continues on the role of galectin-3 in a wide range of diseases, the usefulness of Modified Citrus Pectin will continue to grow as well, offering new hope to patients seeking safe and effective therapies for fighting disease and restoring health naturally. For more information on in the prevention and treatment of cancer visit DrEliaz.org.
Fascinating New Research on Meditation and Brain Health
One of the most beautiful and profound aspects of meditation is that the process of growth and unfolding can continue throughout our lives.
Cancer Research Presented at Naturopathic Oncology Conference
I recently shared research on the role of Modified Citrus Pectin (MCP) as an important nutritional adjunct for supporting long term health at an oncology conference in Arizona.
Botanical Formula Fights Prostate Cancer Without Toxic Side Effects
A pre-clinical study confirms that a powerful botanical formula decreases the expression of PLAU/uPA genes in aggressive, hormone-independent prostate cancer cells.
